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During ovarian gonadotrophin stimulation for ovulation
induction or in vitro fertilization, a clinical severe ovarian
hyperstimulation syndrome (OHSS) may occur. Only few
studies have investigated the mechanism responsible for
the alterations of the haemostatic system in women
affected by severe OHSS. The aim of the present study
was to investigate the correlation between the magnitude
of ovarian stimulation and the increase in fibrin formation
and degradation in severe OHSS. Twenty-five patients (age
range 23–43 years) who were hospitalized for severe
OHSS, 25 women undergoing in vitro fertilization who did
not develop OHSS (case–control group) and 25 healthy
age-matched women (healthy control group) were
investigated. On the day of admission a number of
haemostatic markers, including D-dimer, thrombin–
antithrombin complexes (TAT), prothrombin fragment 1 + 2
(F1 + 2), plasmin–antiplasmin complexes (PAP), tissue
factor (TF), tissue factor pathway inhibitor (TFPI) and von
Willebrand factor antigen (vWF), were examined. In patients
with severe OHSS, TF, D-dimer, TAT, F1 + 2, PAP and vWF
antigen plasma levels were significantly higher than those
observed both in the case–control group and in healthy
controls, whereas TFPI levels were significantly lower
(P < 0.005) with respect to both case–controls and healthy
controls. D-Dimer levels were related with serum
oestradiol levels and oocyte number recovered (r 0.45,
P < 0.001 and r 0.47, P < 0.001, respectively). D-Dimer
and TAT levels were significantly (P < 0.05 and P < 0.005,
respectively) higher in OHSS patients with unsuccessful
pregnancy outcome (D-dimer, 226.5, 56–1449 ng/ml; TAT,
19.8, 3.1–82.6 g/l) with respect to those with successful
outcome of pregnancy (D-dimer, 145, 29–330 ng/ml; TAT,
5.0, 1.0–19.6 g/l). Our data indicate that a marked
hypercoagulability with alterations of TF and TFPI levels is
detectable in patients with severe OHSS and that it is
related to the clinical outcome. Blood Coagul Fibrinolysis
14:277–282 & 2003 Lippincott Williams & Wilkins.
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Introduction
The ovarian hyperstimulation syndrome (OHSS) is a
well-known and serious complication that may occur in
women who undergo controlled ovarian hyperstimula-
tion (COH) cycles with gonadotrophins. This iatrogenic
condition is characterized by a wide spectrum of clinical
and laboratory manifestations including multicystic ovar-
ian enlargement, rapid weight gain, massive extravas-
cular fluid accumulation, combined with intravascular
volume depletion, haemoconcentration, leukocytosis,
oliguria and electrolytic imbalance [1]. Rare, but life-
threatening, complications following the severe forms of
OHSS have been reported, such as thromboembolism,
hypovolaemic shock, liver dysfunction, renal failure and
adult respiratory distress syndrome [2–4].
A precise model to explain the pathophysiology of the
syndrome has not yet been elucidated. Several media-
tors involved in ovulation have been proposed as factors
leading to OHSS such as oestrogens, histamine, cyto-
kines, prostaglandins [5,6] and the ovarian renin–angio-
tensin system [7–10]. The major factor responsible for
OHSS development seems to be human chorionic
gonadotrophin (hCG) [11], exogenously administered or
endogenously produced or, less frequently, luteinizing
hormone [12].
Changes in the haemostatic system have been reported
to be responsible for an increased thrombotic risk in
these patients [13–19], but few studies investigated the
mechanisms responsible for the alterations of the
haemostatic system in women affected by severe
OHSS. In particular, the role of plasma tissue factor
(TF) and of tissue factor pathway inhibitor (TFPI) has
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not been studied until now. TF in complex with
activated factor VII (FVIIa) plays a crucial role in the
initiation of blood coagulation under normal and patho-
logical conditions [20], and TF expression is induced in
monocytes, endothelial cells and vascular smooth mus-
cle cells following activation by proinflammatory cyto-
kines or growth factors [21]. The TF:FVIIa activity is
tightly regulated by TFPI. TFPI is a Kunitz-type
serine protease inhibitor with a potent activity on the
FVIIa/TF complex in the presence of activated factor
X and with a direct inhibiting activity on activated
factor X [22–25].
The present study was undertaken to investigate
hypercoagulability, its correlation with the magnitude
of ovarian stimulation and its possible predictive value
for clinical outcome and involvement of TF and TFPI
in severe OHSS.
Materials and methods
Patients
Twenty-five consecutive patients (age 22–43 years)
admitted to the Obstetrics and Gynecology Depart-
ment of University of Florence, Italy, for severe OHSS
defined according to the criteria of Golan [26] were
prospectively included in our study starting from May
1998 until December 2000. The patients had under-
gone in vitro fertilization and embryo transfer (IVF-ET)
treatment for tubal factors and/or male factor indicators.
All patients with severe OHSS presented ovarian
enlargement, ascites, difficulty of breathing and oligur-
ia. Twenty-five consecutive women in whom OHSS
did not occur (case–control group) after induction of
ovulation were matched by age (23–42 years) and dura-
tion of treatment. In addition, 25 apparently healthy
age-matched (age 22–43 years) women (healthy control
group) were selected as controls. No pregnant woman
or woman on the contraceptive pill was included.
Patients, case–controls and healthy controls had no
personal or familial thromboembolic antecedents and
did not present any known risk factor for thromboem-
bolism. They were enrolled into this study after having
given their informed consent to the use of part of their
blood samples for an experimental study.
In vitro fertilization-embryo transfer
All patients underwent controlled ovarian hyperstimula-
tion IVF-ET. Patients received the gonadotrophin-
releasing hormone analogue triptorelin (Decapeptyl,
Ipsen, France), 0.1 mg subcutaneously daily, from the
mid-luteal phase until hCG administration. Multiple
follicular development was induced by urinary-FSH
(Metrodin HP; Serono Pharma, Rome, Italy) or recom-
binant-FSH (Æ-follitropin; Gonal F 75, Serono) at a
subcutaneous dosage of 150 UI/day. COH was moni-
tored by serum oestradiol (E2) determination and
transvaginal scanning (Aloka SSD 630, Tokyo, Japan)
starting from day 6 of gonadotrophin administration.
When at least three follicles . 17 mm in diameter were
observed and oestradiol levels had reached > 800 pg/
ml, a subcutaneous dose of 10 000 UI hCG (Profasi HP,
Serono, Italy) was administered. After 34–36 h, oocytes
were recovered by transvaginal oocyte pick-up. Three
to four embryos (three in women , 35 years, four in
women . 35 years) were transferred at day 2 or day 3
from oocyte collection.
The luteal phase was supported by the daily intramus-
cular injection of 50 mg natural progesterone (Pronto-
gest, Amsa, Italy). A pregnancy was recorded when a
rise in serum (-subunit) of hCG . 50 UI on day 14
after oocyte retrieval occurred and evidence of a gesta-
tional sac with embryo heart beat was visualized to the
ultrasound scan after a further 2 weeks.
Successful pregnancies occurred in 11 of 25 patients
after the IVF cycle.
In case OHSS signs or symptoms developed, the pa-
tient was invited to have another ultrasound scan and,
in the presence of severe OHSS, she was hospitalized.
Haemostatic studies
Blood samples for haemostasis investigation were ob-
tained immediately after hospitalization (on average
12 days, range 5–30 days, after hCG administration
according to hospital admission for precocious or ‘late
form’ severe OHSS) and before any heparin treatment.
In the case–control group, blood samples were ob-
tained during the mid-luteal phase of treatment cycle.
Venous blood was collected from the antecubital vein
without venous stasis, using a 19-gauge needle, in tubes
(Vacutainer, Becton Dickinson, Meylan, France) con-
taining 0.129 mol/l concentration of sodium citrate (final
ratio with blood 1/10).
Blood samples were preserved and centrifuged at 48C
[for prothrombin fragment 1 + 2 (F1 + 2), thrombin–
antithrombin complex (TAT), plasmin–antiplasmin
complex, (PAP), TF and TFPI assay] or at 188C [for D-
dimer, von Willebrand factor (vWF) assay] (2000 3 g
for 10 min), and plasma was rapidly frozen in liquid
nitrogen and stored at 808C. Within 7 days, aliquots of
plasma were thawed and used for analytical determina-
tions.
F1 + 2, TAT, PAP, D-dimer, vWF, TF and TFPI
plasma levels were determined by enzyme-linked
immunosorbent assay (ELISA) method (Enzygnost
F1 + 2, Enzygnost TAT and Enzygnost PAP; Behrin-
ger, Marburg, Germany; D-Dimer test Gold; Agen,
Brisbane, Australia; vWF; BioMe´rieux, Marcy l’Etoile,
France; IMUBIND Tissue Factor ELISA Kit and
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IMUBIND Total TFPI ELISA Kit; American Diagnos-
tica Inc, Greenwich, Connecticut, USA).
To determine plasma homocysteine, venous blood was
collected in tubes containing 0.17 mol/l ethylenediami-
noacetate, immediately put in ice and centrifuged with-
in 30 min at 48C (1500 3 g for 15 min). The supernatant
was stored in aliquots at 808C until assay. The plasma
levels of total homocysteine (free and protein bound)
were determined by fluorescence polarization immuno-
assay (IMX Abbott Laboratories, Oslo, Norway). Hyper-
homocysteinaemia was diagnosed when fasting plasma
levels exceeded the 95th percentiles of the distribution
of values obtained in controls. All data were corrected
for haematocrit.
Factor V (FV) Leiden and factor II (FII G20210A) gene
mutations were analysed as previously described
[27,28]. Briefly, the FV Leiden mutation was amplified
using as forward primer 59-ACC CAC AGA AAA TGA
TGC CCA G-39 and as reverse primer 59-TGC CCC
ATT ATT TAG CCA GGA G-39 (Pharmacia Biotech,
Milan, Italy). Twenty microlitres of the 223 amplified
products were digested with MnlI (New England
Biolabs, Beverly, Massachusetts, USA) for 4 h at 378C
with 1 U enzyme per reaction. Digestion of normal
allele [223 base pairs (bp)] produced fragments of 37,
82, and 104 bp, whereas digestion of mutated allele
produced fragments of 37 and 141 bp.
The DNA sequence spanning the FII G2021A poly-
morphism was amplified by polymerase chain reaction
using the primer 59-TCT AGA AAC AGT TGC CTG
GC-39 and the mutagenic primer 59-ATA GCA CTG
GGA GCA TTG AAG C-39. The more frequent allele
lacks the restriction site and therefore generates only a
345 bp fragment by HindIII (Pharmacia Biotech) poly-
merase chain reaction digestion, whereas digestion of
mutated allele produced fragments of 322 and 23 bp.
FV Leiden and FII G20210A digestion products were
electrophoresed on 3% agarose gel (Pharmacia Biotech)
and on 8% polyacrylamide gel (Pharmacia Biotech),
respectively, and were visualized by ethidium bromide
staining.
Statistical analysis
The data are presented as median and range. The non-
parametric Kruskal–Wallis test followed by the post-hoc
test were used for multiple comparisons between single
groups. Spearman’s rank correlation coefficient was
used for the correlation analysis.
The results were considered statistically significant at
P , 0.05.
Results
Data of blood haemostatic parameters in patients and
controls are reported in Table 1. In patients with severe
OHSS, D-dimer, TAT, F1 + 2, PAP, and vWF plasma
levels were significantly higher than those observed
both in the case–control group and in healthy controls
(Table 1). D-Dimer levels exceed the 95th percentile
of healthy controls in 20/25, TAT in 21/25 and F1 + 2
in 14/25 OHSS patients.
In severe OHSS patients, TF levels were higher
(P , 0.05) and TFPI levels were lower (P , 0.005) than
those found in both case–controls and healthy controls.
No significant differences in all blood haemostatic
parameters between case–control group and healthy
controls were observed (Table 1).
TAT levels related with D-dimer, PAP and vWF
(r ¼ 0.54, P , 0.0001, r ¼ 0.59, P , 0.0001 and r ¼
0.32, P , 0.001, respectively). D-Dimer values were
related with serum E2 levels and oocyte number
recovered (r ¼ 0.45, P , 0.01 and r ¼ 0.47, P , 0.001,
respectively). Significant relationships were also ob-
served between TFPI and vWF levels (r ¼ 0.37,
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Table 1 Blood haemostatic parameters in patients with ovarian hyperstimulation syndrome (OHSS) and in
control subjects
OHSS (n ¼ 25) Case–controls (n ¼ 25) Healthy controls (n ¼ 25)
Median Range Median Range Median Range P value
D-Dimer (ng/ml) 188.0 (29–1449) 36.0 (2–252) 32.0 (2–124) , 0.0001 , , 0.0001y
TAT (g/l) 7.2 (1.0–82.6) 3.0 (1.7–46.5) 1.9 (0.7–7.5) , 0.05 , , 0.01y
F1 + 2 (nmol/l) 1.8 (0.6–10.0) 0.8 (0.3–2.3) 1.0 (0.6–1.9) , 0.01 , , 0.01y
TF (pg/ml) 108.0 (41–383) 78.6 (21.6–131.6) 75.0 (36.4–92) , 0.05 , , 0.01y
TFPI (ng/ml) 41.4 (18–64.8) 60.0 (28.0–104) 51.0 (34.8–167) , 0.01 , , 0.01y
PAP (g/l) 1423.0 (354–3164) 873.0 (482–1028) 400.0 (137–1017) , 0.0001 , , 0.0001y
vWF (%) 178.0 (87–297) 121.0 (66–210) 106.0 (64–182) , 0.001 , , 0.001y
TAT, thrombin–antithrombin complex; F1 + 2, prothrombin fragment F1 + 2; TF, Tissue factor; TFPI, tissue factor pathway inhibitor;
PAP, plasmin–antiplasmin complex; vWF, von Willebrand factor. OHSS patients versus healthy controls, yOHSS patients versus
case–controls.
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P , 0.01), TFPI and PAP (r ¼ 0.30, P , 0.01) and
TF and TAT (r ¼ 0.32, P , 0.01).
D-Dimer and TAT levels were also related to the
outcome of pregnancy (Table 2): actually, they were
significantly (P , 0.05 and P , 0.005, respectively)
higher in OHSS patients with unsuccessful pregnancy
with respect to those with successful pregnancy out-
come.
In the case–control group, no significant differences
between patients with unsuccessful and successful out-
come were found (data not shown).
In no patients were protein C, protein S and antithrom-
bin levels out of the range of controls (data not shown).
The FII G20210A mutation was found in three OHSS
patients; the FV Leiden G16191A mutation was found
in one OHSS patient and in two case–control subjects,
and mild hyperhomocysteinaemia in two OHSS pa-
tients and in one case–control subject.
All three women with the FII G20210A mutation had
an unsuccessful outcome, whereas the outcome was
successful in the women with the FV Leiden G16191A
mutation and in those with mild hyperhomocysteinae-
mia.
Discussion
Marked alterations in the haemostatic system have
been documented in COH and in severe OHSS
[14,16,17,29]. In this study, clotting activation has been
observed in severe OHSS patients as documented by
increased levels of F1 + 2, TAT and D-dimer. In-
creased thrombin formation and fibrin degradation was
related with high oestrogenaemia, indicating that the
prothrombotic state is probably a consequence rather
than an intrinsic aspect of the pathophysiology of
OHSS. Furthermore, in the group of women under-
going IVF who did not develop OHSS, we did not
observe any significant difference in comparison with
the healthy control group. Therefore, the marked
hypercoagulability observed in OHSS patients seems to
probably be associated with the development of OHSS
rather than the process of IVF. Interestingly, the
present study shows that hypercoagulability was more
marked in women in whom the outcome of the IVF-
ET was unsuccessful. This suggests a role of hypercoa-
gulability in the occurrence of some severe OHSS
complications and supports the concept that these
women are at high risk for thrombotic events. The lack
of significant association in women undergoing IVF,
but who do not develop OHSS between blood clotting
activation markers and outcome suggests that they
could have a role only in conditions in which severe
complications occurs. Antithrombotic prophylaxis is not
widely employed in relation to the possible occurrence
of severe OHSS. Therefore, from a clinical point of
view, the relation of D-dimer levels with clinical out-
come suggests a possible usefulness of monitoring this
parameter in women undergoing COH. However, the
hypothesis of a predictive role of D-dimer for the
outcome of pregnancy should be assessed by ad hoc
studies.
This study is the first report showing a significant
reduction of plasma TFPI, in addition to an increase of
TF plasma levels in severe OHSS patients. TFPI is an
important regulator of the extrinsic blood coagulation
and significantly contributes to the anticoagulant prop-
erties of the endothelium [25,30]. TFPI decrease has
been reported in conditions in which blood clotting
activation occurs [30–32]. The low levels of TFPI
observed in severe OHSS patients might be related to
a reduced hepatic synthesis because low levels of TFPI
have been reported in liver disease [33]. However, in
our patients the concentration of proteins, such as
fibrinogen or prothrombin complex factors or coagula-
tion physiologic inhibitors, were in the normal range, so
making unlikely a relevant defect in liver protein
synthesis in these patients. As plasma TFPI is derived
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Table 2 Blood haemostatic parameters related to outcome of pregnancy
Outcome of pregnancy
Successful (n ¼ 11) Unsuccessful (n ¼ 14)
Median Range Median Range P
D-Dimer (ng/ml) 145.0 29–330 226.5 56–1449 , 0.05
TAT (g/l) 5.0 1–19.6 19.8 3.1–82.6 , 0.005
F1 + 2 (nmol/l) 1.5 0.6–2.5 1.9 0.6–10.0 ns
TF (pg/ml) 91.0 41–192 119.0 49.4–383 ns
TFPI (ng/ml) 32.0 18–53.6 42.9 21–64.8 ns
PAP (g/l) 1369.0 1007–1808 1682.0 354–3164 ns
vWF (%) 190.0 115–297 146.0 87–259 ns
TAT, thrombin–antithrombin complex; F1 + 2, prothrombin fragment F1 + 2; TFPI, tissue factor pathway
inhibitor; PAP, plasmin–antiplasmin complex; vWF, von Willebrand factor; ns, not significant.
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mainly from vascular endothelial cells [34], low levels
of plasma TFPI may rather reflect either an endothelial
dysfunction with impaired TFPI synthesis and secre-
tion or a chronic depletion of the TFPI endothelial
pool [35–37]. Accordingly, in this study the decrease in
TFPI was related to an increase in vWF levels,
suggesting that TFPI exhaustion was associated with
endothelial injury. Moreover, the negative relationship
between TFPI and plasmin formation (assessed by
PAP complex levels), may indicate an increased en-
dothelial t-PA release in severe OHSS patients.
Previous investigations showed increased TF produc-
tion by monocytes from severe OHSS patients [38,39],
but no data were available about TF levels in plasma.
In our study, we have demonstrated for the first time
that TF plasma levels are increased in severe OHSS,
possibly by its release from activated monocyte/macro-
phages and/or vascular endothelial cells. The presence
of high TF in plasma may, in turn, contribute to trigger
blood clotting activation as indicated by the correlation
with TAT. In severe OHSS patients, monocytes and
endothelial cells may be activated or injured by several
mediators. Actually, cytokines and growth factors,
whose increased concentrations have been documented
in this clinical condition [40,41], are able to cause
enhanced TF synthesis and release [42].
In addition to these stimulators, the renin–angiotensin
system may be involved. In experimental animals,
angiotensin II was found to play a role in the develop-
ment of weight gain, third space fluid accumulation and
intravascular fluid depletion in OHSS, and angiotensin-
converting enzyme (ACE) inhibition resulted in a 40%
decrease in the incidence of OHSS [43]. An increased
ACE activity was described to be associated with the
development of OHSS in a clinical report [10]. Further-
more, ACE modulates TF synthesis in monocytes and
ACE inhibitors reduce TF in both in vitro and in vivo
studies [44,45].
In our patients the prevalence of the FII G20210A
mutation was higher than both in controls and in our
laboratory reference group (3% in more than 400
subjects) and, most importantly, it was associated with
negative outcome; however, the limited number of
patients does not allow any further comment.
In conclusion, this study documents the correlation
between the magnitude of ovarian stimulation and
hypercoagulability and the involvement of the TF–
TFPI complex as possible expression of endothelial
dysfunction and monocyte activation in severe OHSS.
Further investigations on a large number of patients are
needed to determine the possible role of markers of
blood clotting activation for the clinical management of
these patients.
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